Campus Access Only

All rights reserved. This publication is intended for use solely by faculty, students, and staff of University of the Pacific. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, now known or later developed, including but not limited to photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author or the publisher.


Design And Evaluation Of Theophylline Monitoring For Home Health Care Patients

Date of Award


Document Type


Degree Name

Doctor of Philosophy (Ph.D.)


The purpose of this study was to design, evaluate, and determine the cost benefit of a pharmacokinetic service for home-based patients. Four randomly selected patient populations were used in evaluating the service for six months. The experimental group consisted of 17 patients who were under the care of family practice physicians in private practice and who received pharmacokinetic consultation and monitoring by a pharmacist as a home health care service. The retrospective control consisted of the same 17 patients of the experimental group whose past medical history for a period of six months was used. The concurrent control consisted of 17 patients who were concurrently treated by the same family practice physicians in private practice who treated the patients in the experimental group. The fourth group consisted of 17 patients who were concurrently treated by family practice physicians in a general hospital outpatient clinic. The service was evaluated by comparing the following variables: serum levels ordered, serum levels ordered inappropriately, physicians' office visits, hospitalizations secondary to pulmonary problems, and emergency room visits secondary to pulmonary problems. A one-way analysis of variance, Scheffe's post hoc test, and t test were used to analyze the results. There was a significant difference (P $<$ 0.05) in the number of inappropriate levels ordered, physician's office visits, and emergency room visits. The cost of the service was $134 and the benefit was \$218. It was concluded that a homebased pharmacokinetic service is cost beneficial in this patient population.



This document is currently not available here.